melphalan


Also found in: Thesaurus, Medical, Acronyms, Wikipedia.

melphalan

(ˈmɛlfəˌlæn)
n
(Pharmacology) a drug, C13H18Cl2N2O2, used to treat myeloid leukaemia
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.melphalan - antineoplastic drug (trade name Alkeran) used to treat multiple myeloma and some other malignanciesmelphalan - antineoplastic drug (trade name Alkeran) used to treat multiple myeloma and some other malignancies
antineoplastic, antineoplastic drug, cancer drug - any of several drugs that control or kill neoplastic cells; used in chemotherapy to kill cancer cells; all have unpleasant side effects that may include nausea and vomiting and hair loss and suppression of bone marrow function
Translations

melphalan

n melfalán m
References in periodicals archive ?
Melphalan is already being used in the clinical setting in the form of intra-arterial delivery and intravitreal injections for treatment of retinoblastoma, and preliminary studies have shown promise [14].
Treatment of AL amyloidosis with high-dose melphalan and stem cell transplantation has proven effective, with a sustained clinical response and reversal of amyloid-related organ dysfunction.
Alkylating agents like melphalan should be avoided as these are damaging to stem cells and will make it difficult to collect stem cell for transplant later.
Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
High-dose melphalan (140-200 mg/[m.sup.2]) and autologous peripheral blood stem-cell transplantation is considered the most effective treatment of AL amyloidosis.
In this report, we describe a case of primary AL amyloidosis in a young patient with isolated kidney involvement and rapid progression to ESRD, treated successfully with melphalan and ASCT.
High-dose melphalan followed by radical radiotherapy for the treatment of massive plasmacytoma of the chest wall.
It also can reduce mucositis associated with high-dose melphalan, Dr.
"Thalidomide is available in the United States, Australia, New Zealand and elsewhere now, and we would like all patients to have safe access to its demonstrated benefits." The combination of melphalan and prednisone (MP) was once the standard of care for myeloma in Europe, but recent studies have shown the combination is greatly improved by the addition of the Novel Therapies: This positive opinion for thalidomide MP is based on a multi-center clinical trial showing average survival of more than 4 years, a year and a half more than MP without thalidomide.
Those given standard therapy of the drugs melphalan and prednisone plus thalidomide survived an average of 51.6 months.
For over 30 years no therapy was superior to oral melphalan and prednisone (MP).
In addition, intermediate doses of melphalan, a potent chemotherapy drug commonly used in multiple myeloma, may provide equivalent activity and less toxicity than does high-dose therapy.